Basic Information
LncRNA/CircRNA Name | H19 |
Synonyms | NA |
Region | GRCh38_11:1995176-2001470 |
Ensemble | ENSG00000130600 |
Refseq | NR_002196 |
Classification Information
Regulatory Mechanism | Biological Function | Clinical Application | |||
---|---|---|---|---|---|
TF | Immune | Survival | |||
Enhancer | Apoptosis | apoptosis | Drug | ||
Variant | Cell Growth | Circulating | |||
MiRNA | EMT | Metastasis | |||
Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
Cancer Name | acute myeloid leukemia |
ICD-0-3 | NA |
Methods | qPCR, Western blot |
Sample | AML cell line Kasumi-1 and human embryonic kidney (HEK)-293T cell line, blood, blood |
Expression Pattern | up-regulated |
Function Description | The expression of lncRNA-H19 in AML patients was markedly higher than that in normal controls and compared with human embryonic kidney (HEK)-293T cells, AML cell Kasumi-1 exhibited an increased lncRNA-H19 expression. LncRNA-H19 could promote cell proliferation, but suppress cell apoptosis. It is bound to micro RNA (miR)-29a-3p in a targeted manner. and the expression level of miR-29a-3p in AML patients was prominently lower than that in normal controls. After miR-29a-3p was inhibited, the expression of intranuclear ?-catenin was significantly increased and the Wnt/?-catenin pathway critical molecules T-cell factor (TCF) and lymphoid enhancer factor 1 (LEF1) were evidently up-regulated after the down-regulation of miR-29a-3p. |
Pubmed ID | 31389605 |
Year | 2019 |
Title | LncRNA-H19 inhibits apoptosis of acute myeloid leukemia cells via targeting miR-29a-3p |
External Links
Links for H19 | GenBank HGNC NONCODE |
Links for acute myeloid leukemia | OMIM COSMIC |